Brain tumor trial delivers targeted toxin directly into tumors
NCT ID NCT02303678
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 1 study tested a drug called D2C7-IT in 81 adults with recurrent malignant glioma (a type of brain tumor). The drug is a lab-made antibody linked to a toxin that targets specific proteins on tumor cells. It was infused directly into the tumor over 72 hours using thin tubes placed during a biopsy. The main goal was to find the safest dose and look for side effects, while also tracking how long patients lived.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- D2C7-IT (a lab-made antibody linked to a toxin that targets certain brain tumor cells)
- What this could lead to
- If it works, this could point toward a new treatment option for people with recurrent malignant brain tumors that are hard to treat.
- What could go wrong
- This is an early phase 1 trial focused on safety and dosing, not yet on effectiveness. The treatment is invasive (delivered directly into the brain) and may cause serious side effects. Many experimental brain tumor treatments fail in later stages.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN TUMOR RECURRENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Preston Robert Tisch Brain Tumor Center at Duke
Durham, North Carolina, 27710, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Spinal fluid DNA test could personalize brain cancer therapy
- Sound waves open brain barrier to deliver cancer drug in kids
- Experimental vaccine aims to rally immune system against recurrent brain cancer
- Immunotherapy drug nivolumab tested in young brain cancer patients
- Brain Tumor's hidden electrical signals could reveal its weaknesses
- New hope for aggressive brain tumors? early trial combines two targeted drugs